AHA 2019 The BETonMACE trial evaluating apabetalone did not reduce the primary composite efficacy outcome, nor key secondary outcomes, in T2DM patients with recent ACS and low HDL-c.
AHA 2019 Prof. McMurray presents the results of an analysis of DAPA-HF comparing the effect of dapagliflozin in HF patients with and without T2DM.
AHA 2019 This analysis of DAPA-HF shows that dapagliflozin consistently reduced worsening HF events and CV death and improved symptoms in patients with HFrEF, irrespective of diabetes status.
A post hoc analysis of ADVANCE and ADVANCE-ON data shows that a eGFR slope of -3 mL/min/1.73m² was associated with increased risk of clinical outcomes in patients with T2DM.
A systematic review and meta-analysis of four trials shows that SGLT2 inhibition reduces the risk for dialysis, kidney transplantation, or death due to kidney disease in T2DM patients.
Based on the CREDENCE renal outcomes trial, the FDA granted the approval of canagliflozin to treat diabetic kidney disease (DKD) and reduction of HF hospitalization in patients with T2DM and DKD.
Dapagliflozin is now approved by the FDA to reduce the risk of hospitalization for HF in T2DM patients with high CV risk.
A meta-analysis of GLP-1RA outcome trials show that treatment reduces the risk of CV and kidney events in T2DM. Subgroup analyses did not explain previously observed differences in trial results.
Prof. Knop gives an overview of potential mechanisms of action of GLP-1RAs to explain observed effects on glycemia, body weight, blood pressure and blood lipids.
Prof. Deanfield explains why these are exciting times for the management of CVD in patients with diabetes and also in those without diabetes.
In the ADDITION-Cambridge population-based study, 30% of participants achieved remission of T2DM after 5 years, mostly those who lost ≥10% body weight early in the T2DM disease trajectory.
CSI Paris Jan Westerink tells about an exploratory analysis of the Look AHEAD trial, using a new prediction model to assess heterogeneity of treatment effects of an intensive lifestyle intervention on occurence of CV events in T2DM.